CathWorks Announces Key Events for EuroPCR 2025
NEWPORT BEACH, Calif. and AMSTERDAM, May 16, 2025 /PRNewswire/ -- CathWorks, a global leader in digital
Loading...
The CathWorks FFRangio® System to be Center Stage, Featured in Multiple Scientific Sessions, Live Cases and a Primetime Academic Satellite Program
NEWPORT BEACH, Calif., Oct. 22, 2025 /PRNewswire/ -- CathWorks, a global leader in digital health innovations, announced today the schedule of key events for the company during the upcoming Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 25 to 28 at the Moscone Center in San Francisco, California.

The CathWorks FFRangio® System will be featured in multiple abstracts and scientific presentations, live cases and an academic satellite program with an all-star faculty. The CathWorks booth will feature hands-on demonstrations with the latest FFRangio technology and peer-to-peer best practice sharing during Expert Exchange sessions hosted by leading physicians.
Scientific Presentations
Live Cases
Academic Satellite Program
"We are extremely pleased that once again, CathWorks will have a prominent presence throughout TCT, underscoring the new era in physiology and shift in the interventional cardiology community towards non-invasive solutions that can not only inform treatment decisions but also guide optimal PCI. We look forward to continuing to work closely with our physician partners to make FFRangio the standard of care across the globe, redefining coronary physiology and its potential," said Ramin Mousavi, President and CEO of CathWorks.
To learn more about CathWorks' events at TCT 2025, visit TCT 2025 - CathWorks or the CathWorks booth #1461 during the conference.
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn.
ALL-RISE: Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment is a multi-center global prospective randomized controlled trial (RCT) aimed at transforming the diagnosis and treatment of coronary artery disease (CAD) by evaluating the clinical and economic benefits of the CathWorks FFRangio® System.Investors:
Mike Feher
[email protected]
Media:
Sarita Monico
[email protected]